Tonix Pharmaceuticals Holding Corp. (TNXP)

In the past six months, Tonix Pharmaceuticals implemented a 1-for-100 reverse stock split on February 5, 2025. The FDA approved Tonmya (TNX-102 SL) for fibromyalgia on August 15, 2025, leading to a significant stock increase followed by a pullback. Positive Phase 3 RESILIENT trial data for TNX-102 SL was published on July 9, 2025. Tonix was added to the Russell 2000 and 3000 indices in June 2025. The company presented data on its pipeline candidates at various conferences and announced the first patient dosed in an investigator-initiated study for intranasal potentiated oxytocin on October 22, 2025. Tonix is scheduled to present at BIO-Europe 2025 on November 4, 2025, and its next earnings report is expected on November 10, 2025.

Demand seasonality for Tonix Pharmaceuticals' products varies by therapeutic area. Fibromyalgia treatments have no specific seasonality. Acute migraine treatments show peaks during seasonal changes in autumn and spring. Mpox/Smallpox vaccine demand is driven by outbreaks and public health initiatives. Cocaine intoxication treatment demand is growing steadily with no identified seasonality. Organ transplant rejection treatment demand may be indirectly influenced by higher winter mortality rates on transplant waitlists and higher kidney transplantation rates in June. Prader-Willi Syndrome treatment demand is driven by increasing prevalence and growth hormone therapy, with no explicit seasonality indicated.

Tonix Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapeutics and vaccines for central nervous system disorders, immunology conditions, infectious diseases, and rare diseases. Its major products and pipeline candidates include Tonmya (TNX-102 SL) for fibromyalgia and other conditions, Zembrace SymTouch and Tosymra for acute migraine, TNX-1300 for cocaine intoxication, TNX-1500 for allograft rejection and autoimmune diseases, TNX-2900 for Prader-Willi syndrome, TNX-801 as a potential vaccine for smallpox and mpox, TNX-1700 for gastric and colorectal cancer, and TNX-4200 as a broad-spectrum antiviral agent.

Tonix Pharmaceuticals is headquartered in Chatham, New Jersey, and New York, New York, with a research and development center in Frederick, Maryland. Clinical trials for Tonmya were conducted across 34 U.S. sites. The company also has operations in Ireland and Canada and has engaged in international collaborations, including with the Kenya Medical Research Institute (KEMRI).

Tonix Pharmaceuticals' brand reputation has been influenced by clinical advancements and market performance, particularly the FDA approval of Tonmya for fibromyalgia. Analyst consensus ratings are mixed, with some "Buy" ratings and some "Sell" indications. News sentiment has been neutral to bullish. The company's inclusion in the Russell 2000 and 3000 indices has enhanced its visibility. However, stock volatility and the reverse stock split have raised some investor concerns.

Tonix Pharmaceuticals has significant institutional ownership, with 114 institutional owners holding a total of 1,893,002 shares. Major institutional shareholders include BlackRock, Inc., Geode Capital Management, Llc, and Vanguard Group Inc. Institutional ownership ranges from approximately 15.94% to 82.26%, while individual ownership stands at approximately 0.08%. Seth Lederman is the CEO of Tonix Pharmaceuticals.